Cargando…
Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten
Infections are an important warning sign for a weakened immune system. In the internal medical practice acquired (secondary), particularly drug-induced immunodeficiencies, are much more frequent than congenital (primary) immunodeficiencies. The management starts as early as the planning phase before...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002026/ https://www.ncbi.nlm.nih.gov/pubmed/35412057 http://dx.doi.org/10.1007/s00108-022-01326-8 |
_version_ | 1784685803906007040 |
---|---|
author | Hanitsch, Leif G. |
author_facet | Hanitsch, Leif G. |
author_sort | Hanitsch, Leif G. |
collection | PubMed |
description | Infections are an important warning sign for a weakened immune system. In the internal medical practice acquired (secondary), particularly drug-induced immunodeficiencies, are much more frequent than congenital (primary) immunodeficiencies. The management starts as early as the planning phase before initiation of immunosuppression. The risk of infection should be individually stratified and protective vaccinations should be completed. Depending on the immunosuppressive treatment, there can be a necessity for preventive treatment, e.g. for latent tuberculosis infection or hepatitis B. The serological results on varicella zoster virus and JC polyomavirus must also be considered. The basic immunological diagnostics include differential blood count and the determination of immunoglobulins (IgG, IgA, IgM) prior to and during immunosuppressive treatment. Relevant conspicuous laboratory results before initiation of treatment should prompt advanced immunological work-up for the identification of primary immunodeficiencies, which are often accompanied by clinical signs of immune dysregulation. Depending on the type of pathogen, localization, frequency and duration as well as the severity of the infection, prophylactic antibiotic treatment may be required. Patients with chronic severe lymphocytopenia, in particular with CD4 positive T (helper) cells < 200/µl, are at increased risk for opportunistic infections so that an antibiotic prophylaxis is recommended. In patients with significantly increased proneness to infections and detection of a relevant quantitative (IgG < 4 g/l) and/or qualitative antibody deficiency (impaired vaccine response), additional immunoglobulin replacement therapy may be necessary and can be administered intravenously (IVIG) or subcutaneously (SCIG) as home treatment. In accordance with the localization of the infection, multidisciplinary clarification and management is warranted. |
format | Online Article Text |
id | pubmed-9002026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-90020262022-04-12 Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten Hanitsch, Leif G. Internist (Berl) Schwerpunkt: Immunität und Infektionsschutz Infections are an important warning sign for a weakened immune system. In the internal medical practice acquired (secondary), particularly drug-induced immunodeficiencies, are much more frequent than congenital (primary) immunodeficiencies. The management starts as early as the planning phase before initiation of immunosuppression. The risk of infection should be individually stratified and protective vaccinations should be completed. Depending on the immunosuppressive treatment, there can be a necessity for preventive treatment, e.g. for latent tuberculosis infection or hepatitis B. The serological results on varicella zoster virus and JC polyomavirus must also be considered. The basic immunological diagnostics include differential blood count and the determination of immunoglobulins (IgG, IgA, IgM) prior to and during immunosuppressive treatment. Relevant conspicuous laboratory results before initiation of treatment should prompt advanced immunological work-up for the identification of primary immunodeficiencies, which are often accompanied by clinical signs of immune dysregulation. Depending on the type of pathogen, localization, frequency and duration as well as the severity of the infection, prophylactic antibiotic treatment may be required. Patients with chronic severe lymphocytopenia, in particular with CD4 positive T (helper) cells < 200/µl, are at increased risk for opportunistic infections so that an antibiotic prophylaxis is recommended. In patients with significantly increased proneness to infections and detection of a relevant quantitative (IgG < 4 g/l) and/or qualitative antibody deficiency (impaired vaccine response), additional immunoglobulin replacement therapy may be necessary and can be administered intravenously (IVIG) or subcutaneously (SCIG) as home treatment. In accordance with the localization of the infection, multidisciplinary clarification and management is warranted. Springer Medizin 2022-04-12 2022 /pmc/articles/PMC9002026/ /pubmed/35412057 http://dx.doi.org/10.1007/s00108-022-01326-8 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Schwerpunkt: Immunität und Infektionsschutz Hanitsch, Leif G. Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title | Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title_full | Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title_fullStr | Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title_full_unstemmed | Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title_short | Prophylaktisches und therapeutisches Management erhöhter Infektionsanfälligkeit bei Immundefekten |
title_sort | prophylaktisches und therapeutisches management erhöhter infektionsanfälligkeit bei immundefekten |
topic | Schwerpunkt: Immunität und Infektionsschutz |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002026/ https://www.ncbi.nlm.nih.gov/pubmed/35412057 http://dx.doi.org/10.1007/s00108-022-01326-8 |
work_keys_str_mv | AT hanitschleifg prophylaktischesundtherapeutischesmanagementerhohterinfektionsanfalligkeitbeiimmundefekten |